CDK inhibitors: Positive and negative regulators of G1-phase progression

Genes and Development

Volumn 13, Issue 12, 1999, Pages 1501-1512

  Sherr, Charles J ^a,b   Roberts, James M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E;

AMINO ACID SUBSTITUTION; CANCER GROWTH; CELL CYCLE G1 PHASE; CHROMATIN STRUCTURE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; ENZYME SUBUNIT; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033564697     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.13.12.1501     Document Type: Review

References (148)

1. Kip1. Mol. Cell. Biol. 17: 3850-3857.
2. ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270: 23589-23597.
3. Alcorta, D.A., Y. Xiong, D. Phelps, G. Hannon, D. Beach, and J.C. Barrett. 1996. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. 93: 13742-13747.
4. INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J. 16: 5322-5333.
5. 1. Genes & Dev. 7: 812-821.
6. Bartkova, J., J. Lukas, and J. Bartek. 1997. Aberrations of the G1-and G1/S-regulating genes in human cancer. Prog. Cell Cycle Res. 3: 211-220.
7. Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J. Biol. Chem. 272: 25863-25872.
8. Blow, J.J. and P. Nurse. 1990. A cdc2-like protein is involved in the initiation of DNA replication in Xenopus egg extracts. Cell 62: 855-862.
9. Brehm, A. and T. Kouzarides. 1999. Retinoblastoma protein meets chromatin. Trends Biochem. Sci. 24: 142-145.
10. Brugarolas, J., C. Chandrasekaran, J.I. Gordon, D. Beach, T. Jacks, and G.J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557.
11. Catzavelos, C., N. Bhattacharya, Y.C. Ung, J.A. Wilson, L. Roncari, C. Sandhu, P. Shaw, H. Yeger, I. Morava-Protzner, L. Kapusta, E. Franssen, K.I. Pritchard, and J.M. Slingerland. 1997. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nat. Med. 3: 227-230.
12. ink4. Mol. Cell. Biol. 15: 2682-2688.
13. Chang, Y., P.S. Moore, S.J. Talbot, C.H. Boshoff, T. Zarkowska, D. Godden-Kent, H. Paterson, R.A. Weiss, and S. Mittnacht. 1996. Cyclin encoded by KS herpes virus. Nature 382: 410.
14. Chellappan, S.P., A. Giordano, and P.B. Fisher. 1998. Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development. Curr. Top. Microbiol. Immunol. 227: 57-103.
15. Chen, J., P.K. Jackson, M.W. Kirschner, and A. Dutta. 1995. Separate domains of p21 involved in the inhibition of cdk kinase and PCNA. Nature 374: 386-388.
16. Cip1. Mol. Cell. Biol. 16: 4673-4682.
17. Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. 95: 1091-1096.
18. Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18: 1571-1583.
19. Clurman, B.E., R.J. Sheaff, K. Thress, M. Groudine, and J.M. Roberts. 1996. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by CDK2 binding and cyclin phosphorylation. Genes & Dev. 10: 1979-1990.
20. Dai, K., R. Kobayashi, and D. Beach. 1996. Physical interaction of mammalian CDC37 with CDK4. J. Biol. Chem. 271: 22030-22034.
21. Deng, C., P. Zhang, J.W. Harper, S.J. Elledge, and P. Leder. 1995. Mice lacking p21Cip1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
22. Diehl, J.A., M. Cheng, M.F. Roussel, and C.J. Sherr. 1998. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes & Dev. 12: 192-229.
23. Dulic, V., E. Lees, and S.I. Reed. 1992. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257: 1958-1961.
24. Dulic, V., W.K. Kaufmann, S.J. Wilson, T.D. Tlsty, E. Lees, J.W. Harper, S.J. Elledge, and S.I. Reed. 1994. p53-Dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023.
25. cdc2 protein kinase. Science 250: 786-791.
26. Dyson, N. 1998. The regulation of E2F by pRB-family proteins. Genes & Dev. 12: 2245-2262.
27. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
28. Elledge, S.J. and J.W. Harper. 1994. CDK inhibitors: On the threshold of check points and development. Curr. Opin. Cell. Biol. 6: 847-852.
29. Kip cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J. 18: 644-653.
30. Ewen, M.E., H.K. Sluss, C.J. Sherr, H. Matsushime, J.-Y. Kato, and D.M. Livingston. 1993. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73: 487-497.
31. Ezhevsky, S.A., H. Nagahara, A.M. Vocero-Akbani, D.R. Gius, M.C. Wei, and S.F. Dowdy. 1997. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc. Natl. Acad. Sci. 94: 10699-10704.
32. Fang, F. and J.W. Newport. 1991. Evidence that the G1-S and G2-M transitions are controlled by different cdc2 proteins in higher eukaryotes. Cell 66: 731-742.
33. Fantl, V., G. Stamp, A. Andrews, I. Rosewell, and C. Dickson. 1995. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes & Dev. 9: 2364-2372.
34. Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177-180.
35. Filmus, J., A.I. Robles, W. Shi, M.J. Wong, L.L. Colombo, and C.J. Conti. 1994. Induction of cyclin D1 overexpression by activated ras. Oncogene 9: 3627-3633.
36. Girard, F., U. Strausfeld, A. Fernandez, and N.J.C. Lamb. 1991. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67: 1169-1179.
37. Gu, Y., C.W. Turek, and D.O. Morgan. 1993. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366: 707-710.
38. INK4b/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes & Dev. 8: 2939-2952.
39. Haas, K., P. Staller, C. Geisen, J. Bartek, M. Eilers, and T. Moroy. 1997. Mutual requirement of CDK4 and Myc in malignant transformation: evidence for cyclin D1/CDK4 and p16INK4a as upstream regulators of Myc. Oncogene 15: 179-192.
40. Hall, M., S. Bates, and G. Peters. 1995. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11: 1581-1588.
41. INK4b is a potential effector of TGFβ-induced cell cycle arrest. Nature 371: 257-261.
42. CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16: 859-867.
43. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
44. Harper, J.W., S.J. Elledge, K. Keyomarsi, B. Dynlacht, L.H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, M.P. Fox, and N. Wei. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6: 387-400.
45. Hatakeyama, M., J.A. Brill, G.R. Fink, and R.A. Weinberg. 1994. Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes & Dev. 8: 1759-1771.
46. Hengst, L. and S. Reed. 1998a. Inhibitors of the Cip/Kip family. Curr. Top. Microbiol. Immunobiol. 227: 25-41.
47. Cip1. Genes & Dev. 12: 3882-3888.
48. Herrera, R.E., V.P. Sah, B.O. Williams, T.P. Makela, R.A. Weinberg, and T. Jacks. 1996. Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol. Cell. Biol. 16: 2402-2407.
49. Hinds, P.W., S. Mittnacht, V. Dulic, A. Arnold, S.I. Reed, and R.A. Weinberg. 1992. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70: 993-1006.
50. Hirai, H., M.F. Roussel, J. Kato, R.A. Ashmun, and C.J. Sherr. 1995. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15: 2672-2681.
51. Hurford, R.K.J., D. Cobrinik, M.-H. Lee, and N. Dyson. 1997. pRB and P107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes & Dev. 9: 2364-2372.
52. Jackson, P.K., S. Chevalier, M. Philippe, and M.W. Kirschner. 1995. Early events in DNA replication require cyclin E and are blocked by p21CIP1. J. Cell Biol. 130: 755-769.
53. INK4a-mediated growth suppression. Mol. Cell. Biol. 18: 5284-5290.
54. Johnson, D.G., J.K. Schwarz, W.D. Cress, and J.R. Nevins. 1993. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365: 349-352.
55. Kato, J.-Y., H. Matsushime, S.W. Hiebert, M.E. Ewen, and C.J. Sherr. 1993. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase, CDK4. Genes & Dev. 7: 331-342.
56. Kip1) of cyclin-dependent kinase-4 activation. Cell 79: 487-496.
57. Kelly, B.L., K.G. Wolfe, and J.M. Roberts. 1998. Identification of a substrate-targeting domain in cyclin E necessary for phosphorylation of the retinoblastoma protein. Proc. Natl. Acad. Sci. 95: 2535-2540.
58. Kerkhoff, E. and U.R. Rapp. 1997. Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol. Cell. Biol. 17: 2576-2586.
59. King, R.W., R.J. Deshaies, J.-M. Peters, and M.W. Kirschner. 1996. How proteolysis drives the cell cycle. Science 274: 1652-1659.
60. Kitagawa, M., H. Higashi, H.K. Jung, I. Suzuki-Takahashi, M. Ikeda, K. Tamai, J. Kato, K. Segawa, E. Yoshida, S. Nishimura, and Y. Taya. 1996. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 15: 7060-7069.
61. Kiyokawa, H. and A. Koff. 1998. Roles of cyclin-dependent kinase inhibitors: Lessons from knockout mice. Curr. Top. Microbiol. Immunol. 227: 105-120.
62. Knoblich, J.A., K. Sauer, L. Jones, H. Richardson, R. Saint, and C.F. Lehner. 1994. Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis and is required for the arrest of cell proliferation. Cell 77: 107-120.
63. Koff, A., F. Cross, A. Fisher, J. Schumacher, K. Leguellec, M. Philippe, and J.M. Roberts. 1991. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66: 1217-1228.
64. Koff, A., A. Giordano, D. Desai, K. Yamashita, J.W. Harper, S. Elledge, T. Nishimoto, D.O. Morgan, B.R. Franza, and J.M. Roberts. 1992. Formation and activation of a cyclin E-CDK2 complex during the G1 phase of the human cell cycle. Science 257: 1689-1694.
65. Koff, A., M. Ohtsuki, K Polyak, J.M. Roberts, and J. Massagué. 1993. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 260: 536-539.
66. Koh, J., G.H. Enders, B.D. Dynlacht, and E. Harlow. 1995. Tumour-derived p16 alleles encoding proteins defective in cell cycle inhibition. Nature 375: 506-510.
67. Krude, T., M. Jackman, J. Pines, and R.A. Laskey. 1997. Cyclin/ cdk-dependent initiation of DNA replication in a human cell-free system. Cell 88: 109-119.
68. LaBaer, J., M.D. Garrett, L.F. Stevenson, J.M. Slingerland, C. Sandhu, H.S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes & Dev. 11: 847-862.
69. Lamphere, L., F. Fiore, X. Xu, L. Brizuela, S. Keezer, C. Sardet, G.F. Draetta, and J. Gyuris. 1997. Interaction between Cdc37 and Cdk4 in human cells. Oncogene 14: 1999-2004.
70. Latham, K.M., S.E. Eastman, A. Wong, and P.W. Hinds. 1996. Inhibition of p53-mediated growth arrest by overexpression of cyclin-dependent kinases. Mol. Cell. Biol. 16: 4445-4455.
71. MAPK pathway. J. Biol. Chem. 271: 20608-20616.
72. Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes & Dev. 9: 639-649.
73. WAF-1 gene activities. Mol. Biol. Cell 16: 1786-1793.
74. Loda, M., B. Cukor, S.W. Tam, P. Lavin, M. Fiorentino, G.F. Draetta, J.M. Jessup, and M. Pagano. 1997. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3: 231-234.
75. Ludlow, J.W., J. Shon, J.M. Pipas, D.M. Livingston, and J.A. DeCaprio. 1990. The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T. Cell 60: 387-396.
76. Ludlow, J.W., C.L. Glendening, D.M. Livingston, and J.A. DeCaprio. 1993. Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol. Cell. Biol. 13: 367-372.
77. Lukas, J., H. Muller, J. Bartkova, D. Spitkovsky, A.A. Kjerulff, P. Jansen-Durr, M. Strauss, and J. Bartek. 1994. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J. Cell Biol. 125: 625-638.
78. Lukas, J., J. Bartkova, M. Rohde, M. Strauss, and J. Bartek. 1995a. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells, independent of CDK4 activity. Mol. Cell. Biol. 15: 2600-2611.
79. Lukas, J., D. Parry, L. Aagaard, D.J. Mann, J. Bartkova, M. Strauss, G. Peters, and J. Bartek. 1995b. Retinoblastoma protein-dependent cell cycle inhibition by the tumor suppressor p16. Nature 375: 503-506.
80. Lukas, J., T. Herzinger, K. Hansen, M.C. Moroni, D. Resnitzky, K. Helin, S.I. Reed, and J. Bartek. 1997. Cyclin E-induced S phase without activation of the Rb/E2F pathway. Genes & Dev. 11: 1479-1492.
81. Lundberg, A.S. and R.A. Weinberg. 1998. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-CDK complexes. Mol. Cell. Biol. 18: 753-761.
82. Mahony, D., D.A. Parry, and E. Lees. 1998. Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells. Oncogene 13: 603-611.
83. Kip1 levels by the cyclin encoded by Kaposi's sarcoma-associated virus. EMBO J. 18: 654-663.
84. CIP1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes & Dev. 9: 650-662.
85. PSKJ3/CDK4) for mammalian D-type G1 cyclins. Cell 71: 323-334.
86. Matsushime, H., D.E. Quelle, S.A. Shurtleff, M. Shibuya, C.J. Sherr, and J.-Y. Kato. 1994. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14: 2066-2076.
87. INK4a inhibits both CDK4-and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol. Cell. Biol. 19: 1981-1989.
88. ink4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. 92: 6289-6293.
89. Meyerson, M. and E. Harlow. 1994. Identification of a G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol. 14: 2077-2086.
90. INK4a. Mol. Cell. Biol. 19: 3916-3928.
91. Mittnacht, S., J.A. Lees, D. Desai, E. Harlow, D.O. Morgan, and R.A. Weinberg. 1994. Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J. 13: 118-127.
92. Morse, L., D. Chen, D. Franklin, Y. Xiong, and S. Chen-Kiang. 1997. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity 6: 47-56.
93. Sdi1/CIP1/WAF1. EMBO J. 14: 555-563.
94. Nakayama, K. 1998. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. BioEssays 12: 1020-1029.
95. Nevins, J.R. 1998. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. 9: 585-593.
96. Noda, A., Y. Ning, S.F. Venable, O.M. Pereira-Smith, and J.R. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell. Res. 211: 90-98.
97. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570-573.
98. Ohtsubo, M., A.M. Theodoras, J. Schumacher, J.M. Roberts, and M. Pagano. 1995. Human cyclin E, a nuclear protein essential for the G1 to S phase transition. Mol. Cell. Biol. 15: 2612-2624.
99. Pagano, M., R. Pepperkok, F. Verde, W. Ansorge, and G. Draetta. 1992. Cyclin A is required at two points in the human cell cycle. EMBO J. 11: 961-971.
100. Palmero, I., B. McConnell, D. Parry, S. Brookes, E. Hara, S. Bates, P. Jat, and G. Peters. 1997. Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. Oncogene 15: 495-503.
101. INK4/MTS1 tumor suppressor gene product. EMBO J. 14: 503-511.
102. Parry, D.A., D. Mahony, K. Wills, and E. Lees. 1999. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol. Cell. Biol. 19: 1775-1783.
103. Peeper, D.S., T.M. Upton, M.H. Ladha, E. Neuman, J. Zalvide, R. Bernards, J.A. DeCaprio, and M.E. Ewen. 1997. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386: 177-181.
104. Peters, J.-M. 1998. SCF and APC: The Yin and Yang of cell cycle regulated proteolysis. Curr. Opin. Cell Biol. 10: 759-768.
105. Phelps, D.E., K.M. Hsiao, Y. Li, N. Hu, D.S. Franklin, E. Westphal, E.Y. Lee, and Y. Xiong. 1998. Coupled transcriptional and translational control of cyclin-dependent kinase inhibitor p18INK4c expression during myogenesis. Mol. Cell. Biol. 18: 2334-2343.
106. Kip1, a cyclin-cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes & Dev. 8: 9-22.
107. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66.
108. Porter, P.L., K.E. Malone, P.J. Heagerty, G.M. Alexander, L.A. Gatti, F.J. Firpo, J.R. Daling, and J.M. Roberts. 1997. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3: 222-225.
109. Qin, X.Q., D.M. Livingston, W.G. Kaelin, Jr., and P.D. Adams. 1994. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. 91: 10918-19022.
110. 1 phase in rodent fibroblasts. Genes & Dev. 7: 1559-1571.
111. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes & Dev. 11: 492-503.
112. Reynisdóttir, I., K. Polyak, A. Iavarone, and J. Massagué. 1995. Kip/Cip and Ink4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes & Dev. 9: 1831-1845.
113. INK4a/CDKN2A tumor suppressor and its relatives. B.B.A. Rev. Cancer 1378: F115-F177.
114. Russo, A.A., P.D. Jeffrey, A.K. Patten, J. Massagué, and N.P. Pavletich. 1996. Crystal structure of the p27Kip1 cyclin-dependent kinase inhibitor bound to the cyclin A-cdk2 complex. Nature 382: 325-331.
115. Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
116. INK4a. Cell 88: 593-602.
117. Shan, B. and W.H. Lee. 1994. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol. 14: 8166-8173.
118. Sheaff, R., M. Groudine, M. Gordon, J. Roberts, and B. Clurman. 1997. Cyclin E-CDK2 is a regulator of p27Kip1. Genes & Dev. 11: 1464-1478.
119. Sherr, C.J. 1993. Mammalian G, cyclins. Cell 73: 1059-1065.
120. _. 1996. Cancer cell cycles. Science 274: 1672-1677.
121. 1 cyclin-dependent kinases. Genes & Dev. 9: 1149-1163.
122. Sicinski, P., J.L. Donaher, S.B. Parker, T. Li, A. Fazeli, H. Gardner, S.Z. Haslam, R.T. Bronson, S.J. Elledge, and R.J. Weinberg. 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82: 621-630.
123. Sicinski, P., J.L. Donaher, Y. Geng, S.B. Parker, H. Gardner, M.Y. Park, R. Robker, J.S. Richards, L.K. McGinnis, J.D. Biggers, J.J. Eppig, R.T. Bronson, S.J. Elledge, and R.A. Weinberg. 1996. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384: 470-471.
124. Soos, T.J., H. Kiyokawa, J.S. Yan, M.S. Rubin, A. Giordano, A. DeBlasio, S. Bottega, B. Wong, J. Mendelsohn, and A. Koff. 1996. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ. 7: 135-146.
125. Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes & Dev. 10: 1491-1502.
126. Stillman, B. 1996. Cell cycle control of DNA replication. Science 274: 1659-1664.
127. Strausfeld, U.P., M. Howell, P. Descombes, S. Chevalier, R.E. Rempel, J. Adamczewski, J.L. Maller, T. Hunt, and J.J. Blow. 1996. Both cyclin A and cyclin E have S-phase promoting (SPF) activity in Xenopus egg extracts. J. Cell Sci. 109: 1555-1563.
128. Swanton, C., D.J. Mann, B. Fleckenstein, F. Neipel, G. Peters, and N. Jones. 1997. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390: 184-187.
129. Taya, Y. 1997. RB kinases and RB-binding proteins: New points of view. Trends Biochem. Sci. 22: 14-17.
130. Toyoshima, H. and T. Hunter. 1994. p27, a novel inhibitor of G1 cyclin/cdk protein kinase activity, is related to p21. Cell 78: 67-74.
131. Tsihlias, J., L. Kapusta, and J. Slingerland. 1999. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50: 401-423.
132. van den Heuvel, S. and E. Harlow. 1993. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262: 2050-2054.
133. Kip1. EMBO J. 16: 5334-5344.
134. WAF1 and proliferating cell nuclear antigen. Curr. Biol. 5: 275-282.
135. 1 phase. Biochem. J. 326: 61-68.
136. Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
137. WAF1/ CIP1 mutants deficient in inhibiting cyclin-dependent (CDKs) can promote assembly of active cyclin D/CDK4(6) complexes in human tumor cells. Cancer Res. 58: 5053-5056.
138. Winston, J.T., S.R. Coats, Y.-Z. Wang, and W.J. Pledger. 1996. Regulation of the cell cycle machinery by oncogenic ras. Oncogene 12: 127-134.
139. Won, K.-A. and S.I. Reed. 1996. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J. 15: 4182-4193.
140. Xiong, Y., G.J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993a. p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
141. Xiong, Y., H. Zhang, and D. Beach. 1993b. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes & Dev. 7: 1572-1583.
142. Zhang, H., G.J. Hannon, and D. Beach. 1994. p21-containing cyclin kinases exist in both active and inactive states. Genes & Dev. 8: 1750-1758.
143. INK4a, TGFβ, and contact inhibition. Cell 97: 53-61.
144. Zhao, J., B. Dynlacht, T. Imai, T. Hori, and E. Harlow. 1998. Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. Genes & Dev. 12: 456-461.
145. Zindy, F., E. Lamas, X. Chenivesse, J. Sobczak, J. Wang, D. Fesquet, B. Henglein, and C. Brechot. 1992. Cyclin A is required in S phase in normal epithelial cells. Biochem. Biophys. Res. Commun. 182: 1144-1154.
146. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15: 203-211.
147. Zindy, F., H. Soares, K.-H. Herzog, J. Morgan, C.J. Sherr, and M.F. Roussel. 1997b. Expression of INK4 inhibitors in cyclin D-dependent kinases during mouse brain development. Cell Growth Differ. 8: 1139-1150.
148. Zwicker, J., S. Brusselbach, K.U. Jooss, A. Sewing, M. Behn, F.C. Lucibello, and R. Muller. 1999. Functional domains in cyclin D1: pRb-kinase activity is not essential for transformation. Oncogene 18: 19-25.